Skip to search formSkip to main contentSkip to account menu

Poly(ADP-Ribose) Polymerase Inhibitors [MoA]

Known as: Poly ADP Ribose Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase Inhibitors, Poly ADP-Ribose Polymerase Inhibitors 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Purpose: To define the prevalence of HER2 positive breast cancer (HER2+ BC) in women with gBRCA1/2-BC and to determine whether… 
2019
2019
Introduction: Ovarian cancer is a rare but often fatal disease and a leading cause of gynecologic cancer death, in the United… 
Review
2018
Review
2018
Epithelial ovarian cancer (EOC) is a common malignant disease, which remains asymptomatic for a prolonged period of time and is… 
2018
2018
Poly(ADP-ribose) polymerase inhibitors (PARPi) are targeted therapeutics with enhanced selectivity and cytotoxicity in BRCA1/2… 
Highly Cited
2016
Highly Cited
2016
Poly(ADP-ribose) polymerase inhibitors (PARPIs) kill cancer cells by trapping PARP1 and PARP2. Talazoparib, the most potent PARPI… 
Highly Cited
1996
Highly Cited
1996
Injury and inflammation lead to hypoxia and elevated lactate in wounds. This redox environment establishes cells in a reparative…